August - 20216Aug - 2 - 2021, volume 05 - Issue 4 (ISSN 2691-4093)Published by ValleyMedia, Inc. Managing EditorAlex D'souzaEditorial StaffVisualizerJohn GothamSalesAndrew D'Souzaandrew.dsouza@medicaltechoutlook.com510.996.5123Contact usEmailPhone:510 230 0396 Fax:510-894-8405sales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comJoshua Parker Merlin WatsonJoe Philip Laura PintoTo subscribe to MedicalTech OutlookVisit www.medicaltechoutlook.com Copyright © 2021 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffAlex D'souzaManaging Editoreditor@medicaltechoutlook.comHealthcare investment keeps on increasing substantially in recent years. Such investment has also focused on fighting major diseases, enabled by the novel invention of cost-effective and valid drug development for treatment and side effect reduction, along with improved vector control. In addition, the demand for diagnostics is essential in determining prognosis, identifying disease stages, monitoring treatment, and assessing the spreading as health services have significantly expanded. However, classic diagnostic technologies are not entirely well suited to meeting the expanded testing requirement because they rely on complicated sample purification and sophisticated instruments, which are labour-intensive, timely, and expensive and require well-trained operators. One of the main challenges for the industry is to develop fast, relatively accurate, easy-to-use, and inexpensive devices. While in vitro diagnostics (IVDs) support clinical and personal decision making, they do not directly drive health outcomes. Unlike other medical devices that provide therapy, most IVDs never even come into contact with patients. Considered the "silent champion" of healthcare, IVDs are extremely valuable resources for disease prevention, detection and management. As an industry ­ manufacturers, healthcare professionals and regulators alike ­ we must not understate or overlook the power of IVDs in the fight against disease worldwide.In this edition of MedTech Outlook, we bring you the story of some of the most successful In Vitro diagnostic solution providers across Europe and the UK that deliver the best outcomes for their clients. In addition, expert contributors also discuss IVF and the potential of future research, offering essential information for business leaders to IVF practitioners. Also, this special edition will guide the readers through every step of human-assisted conception, from patient pre-treatment to monitoring of outcomes. We hope this issue will provide you with the proper assistance in choosing the best MedTech vendor according to your requirements.Let us know your thoughts.The Future of Nascent In Vitro Diagnostics IndustrySarah FernandesEDITORIAL
< Page 5 | Page 7 >